Hawley Urges DOJ to ‘Reconsider’ Stance in Missouri Mifepristone Case

Wednesday, May 07, 2025

Today, Senator Hawley (R-Mo.) sent a letter to Attorney General Pam Bondi, urging the Justice Department to reconsider its defense of the Biden Administration’s policy on mifepristone, which allows women to receive the abortion drug with virtually no safeguards. The case is currently pending before a federal district court. 

A bombshell new study found that more than 1 in 10 women who use mifepristone experience sepsis, infection, hemorrhaging, an emergency room visit, or another serious adverse event within 45 days. The report exposes just how essential reestablishing these guardrails are for women’s health. 

“While the grounds for dismissal sought are mostly procedural in nature, I am troubled by the fact that the Justice Department has sided with the Biden administration’s position, especially considering new data showing the harms of chemical abortion for women,” Hawley wrote. “I urge you to reconsider.”

Senator Hawley recently published an op-ed about the health risks of mifepristone and called on the Trump administration to restore the safety regulations on mifepristone without delay. 

Read the letter here or below.  

May 7, 2025

The Honorable Pam Bondi Attorney General
U.S. Department of Justice 
950 Pennsylvania Avenue NW
Washington DC 20530

Attorney General Bondi:

Yesterday, your department sought the dismissal of three intervenor state plaintiffs—led by my home state of Missouri—in abortion drug litigation pending before a federal district court. While the grounds for dismissal sought are mostly procedural in nature, I am troubled by the fact that the Justice Department has sided with the Biden administration’s position, especially considering new data showing the harms of chemical abortion for women. I urge you to reconsider.

Missouri, joined by Idaho and Kansas, is seeking to restore safeguards for the chemical abortion drug, mifepristone, that the Biden administration eliminated. The states have argued their interest in protecting their citizens against the adverse health consequences of the drug—a point which was recently underscored by a landmark new study of mifepristone. That study found that more than 1 in 10 women who use mifepristone experience sepsis, infection, hemorrhaging, an emergency room visit, or another serious adverse event within 45 days. This rate is far greater than the rate reported on the FDA-approved drug label for mifepristone. Despite these severe safety risks, the Biden administration allowed mifepristone to be delivered via mail and without any medical supervision whatsoever. Missouri’s litigation aims to reverse that policy and protect women.

The Biden administration’s mail-order abortion policy poses a grave threat to the health and safety of American women. I strongly urge you to reconsider the Justice Department’s defense of this policy in court.

Thank you for your attention to this matter.

Sincerely,

Josh Hawley
United States Senator

###

Issues